-
Replys to Correspondence
Reply to correspondence on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
- Hiroaki Kanzaki, Yujin Hoshida
- Clin Mol Hepatol. 2025;31(1):e121-e122.
-
Editorials
Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial”
- Hiroaki Kanzaki, Yujin Hoshida
- Clin Mol Hepatol. 2025;31(1):308-310.
-
Reviews
Switching to systemic therapy after locoregional treatment failure: Definition and best timing
- Sadahisa Ogasawara, Yoshihiko Ooka, Keisuke Koroki, Susumu Maruta, Hiroaki Kanzaki, Kengo Kanayama, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Naoya Kanogawa, Tomoko Saito, Takayuki Kondo, Eiichiro Suzuki, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Jun Kato, Naoya Kato
- Clin Mol Hepatol. 2020;26(2):155-162.